0 Products u$d 0,00

Cart

Dexa 20
Corticoid anti-inflammatory
(Code: 0026-0013)

Price:u$d 16,77

A High concentration and quick effect anti-inflammatory glucocorticoid.
COMPOSITION
Dexamethasone sodium 21 phosphate to the maximum concentration of 20 mg/mL.

DEXA 20 (Dexamethasone 21 Sodium phosphate USP) is a strong corticosteroid anti-inflammatory of maximum concentration and quick action.

It is especially adequate for emergency intravenous administration due to its high concentration in a scarce volume injected.

Pharmacokinetics:

The drug flows in plasma connected with proteins conveyor, the rest is done as a free hormone. Cortisol is conjugated in the liver with glucuronates and soluble sulphates, which are excreted by urine.

BIOACTIVITY:

DEXA 20 (Dexamethasone 21 Sodium phosphate USP) has an anti-inflammatory potency 30 times greater than cortisol and a mineral-corticoid relative activity of 0 in comparison with 1 to 2 as for Cortisol.

Its plasmatic life average is 119 - 300 minutes, and its effect length after parenteral administration is more than 48 hours.

DEXA 20 has varied effects on different systems:

• At cardiovascular level, it reduces the capillary permeability thus avoiding vasoconstriction.

It has a positive inotropic effect, thus increasing –slightly- blood pressure.

• At renal, fluids and electrolytes level, it increases potassium and calcium excretion, sodium and chloride re-absorption and the extra-cellular fluid volume.

• At metabolic level, it stimulates the gluconeogenesis thus increasing the glycemia. It increases the hepatic reserves of glycogen.

• At cellular level, it stabilizes the cellular membranes; it inhibits proliferation of fibroblasts and macrophages; and inhibits lymphocytes and cellular mediators of inflammation going numb.

• At central and autonomous nervous system, it reduces the response to pyrogens, and stimulates the appetite.

• At hematopoietic level, it increases the amount of platelets, neutrophils, and circulating erythrocytes.

DOSAGE:

Reference dose in shock (all species): 4 to 8 mg/kg. (Equivalent to 2 - 4 ml/10 kg). Intravenous via.

• Equines, bovines, ovine and porcine: 0,05 - 0,2 mg/kg. (Equivalent to 0,125 to 0,5 ml/50 kg). Intravenous, intramuscular or subcutaneous via.

• Canines and felines: 0,1 to 2 mg/kg. (Equivalent to 0,05 - 1,0 ml/10 kg). Intravenous, intramuscular or subcutaneous via.

Reference dose depending on the different clinical uses:

• Hypovolemic shock or dehydratation: 4 to 8 mg/kg intravenous via, simultaneously with Fluid Therapy and internal medium equilibrium.

• Anaphylactic shock: 4 to 8 mg/kg intravenous via.

• Supportive therapy in shock due to acute gastric dilatation, volvulus or intestinal torsion: 3 mg/kg intravenous via.

• Endotoxic shock prevention: 5 mg/kg slowly intravenous via.

• Bronchial asthma, allergic bronchitis: 0,25 to 1,0 mg/kg from 1 to 3 times per day.

Acquired thrombocytopenia: 0,25 to 0,3 mg/kg intravenous or subcutaneous via, one application, then continue with 0,1 to 0,15 mg/kg twice a day during 7 days.

• Cranial, cerebral and/or spinal traumatism: initially, administer a bolus injection intravenous via 2 mg/kg, then continue with 0,2 mg/kg twice or three times per day.

• Spinal traumatism, disk dislocation with paresis, spondylopathy: Administer 2 to 3 mg/kg intravenous via before the 6 - 8 hours after the traumatism, continue with 1 mg/kg twice or three times a day subcutaneous or intramuscular via during the next 24 hours; it will be continued during 2 or 3 days with 0,2 mg/kg every 12 hours and then, during 3 to 5 days with 0,1 mg/kg every 12 hours.

• Delivery induction or therapeutic abortion:

- Abortions: 25 mg/kg combined with 25 mg of Prostaglandin F2 Alfa, 150 days after gestation (Bovines y Equines).

- Delivery induction: until 2 weeks before the approximate delivery date, administer 20 to 30 mg/kg intramuscular via.

• Intracranial edema: 0,25 to 2,0 mg/kg every 6 hours intravenous via.

• Hydrocephaly: 0,25 mg/kg three or four times per day. Then, slowly reduce the dose after 2 to 4 weeks of treatment.

• Fibro-cartilaginous myopathy or post traumatic adherences: 2,2 mg/kg every 6 to 8 hours subcutaneous via, then continue with 0,1 mg/kg every 12 hours during 3 to 5 days.

•Obturator and/or peroneal nerve paresis: 10 to 30 mg/kg, once a day, during 2 or 3 days. Subcutaneous or intramuscular via.

• Aseptic Laminitis: 5 to 20 mg/kg intravenous o intramuscular via, once a day, during 2 or 3 days.

• Ketosis: 5 to 20 mg/kg intravenous or intramuscular via.

ADMINISTRATION:

All via injectable solution.

PRESENTATION:

20 ml Vial.

OBSERVATION:

DEXA 20 (Dexamethasone 21 Sodium phosphate USP), is indicated in emergency therapeutic in several shock states, anaphylaxis, bronchospasm, cranial-encephalic traumatisms, spinal compression syndrome, backache, neuralgia and neuropathy, arthropathy, myalgia and myopathy, tendinitis, bursitis, autoimmune diseases, stress, anorexic syndrome and sport animal azoturia.

DEXA 20 could be used in dermatological and respiratory allergies, bronchial asthma, ketosis and as a labour inducer agent.

DEXA 20 influences the microcirculation, thus producing a vasodilatation held up by beta 2 adrenergic action at capillaries level, improving the renal and tissue perfusion and, protecting tissues against hypoxia and acidosis, thus stabilizing the lysosomal membranes. This activity makes DEXA a drug to the used –especially- to stabilize patients in shock.

Compatibility:

Injectable Dexamethasone 21 Sodium phosphate USP is compatible with: amikacin sulphate, aminophylline, bleomycin sulphate, cimetidine, glycopirrolate and lidocaine HCl.

Compatibility depends on pH, concentration, temperature, and used diluents.

Incompatibility:

Injectable Dexamethasone 21 Sodium phosphate USP is incompatible with: doxorubicin, daunorubicin and vancomycin.

CONTRAINDICATED:

• Systemic corticoids usage is contraindicated in fungal, viral and bacterial infections when the adequate antibiotic-therapy has not been put into action.

• In extended treatments, the ACTH inhibition recovery time should be taken into account; ACTH function will slowly normalized once the treatment is discontinued.

• Remember that high doses of corticoids in the last third of pregnancy can induce to labour; occasionally, this effect is followed by dystocia, foetal death, retained placenta, and metritis.

• Do not administer in animals with uremic syndrome, glaucoma, diabetes mellitus, acute laminitis, general ulcerative processes, tuberculosis, paratuberculosis, leptospirosis in incubation period and in vaccination periods.

• Do not use in dairy cattle in lactation, whose product is destined to human consumption.

COLLATERAL EFFECTS:

• Normally, collateral effects are associated to extended treatments, specially at high doses without respecting the indication about alternating days. Symptoms are shown as hypoadrenocorticism.

• In young animals, the development could be delayed.

• In canines, effects such us polydipsia, polyuria and polyphagia were described. Adverse effects in canines are associated to sadness, weight gain, fur change, vomiting, diarrhea, hepatic and pancreatic enzymes elevation, gastric ulcers, change of behaviour, and diabetes mellitus exacerbation. These symptoms are reverted once corticoids administration is discontinued.

• There were found teratogenic effects in massive treatments in females with early gestation (cleft palate, bony deformations).

• When the drug is administered as an anti-inflammatory agent with extremely short action, it is unusual to find collateral effects different from polydipsia, polyuria, and temporary polyphagia.

RESTRICTIONS:

It is suggested not to vaccinate the animals under extended treatment with corticoids; if necessary, a revaccination should be done once the treatment is finished.

PRECAUTIONS:

• Regarding the product and the animal, all routine asepsis and antisepsis conditions should be kept, in order to preserve sterility, avoid its chemical contamination and prevent accidents after application manoeuvre.

• Suggested doses and warnings are to be determined by the veterinarian in charge.

• Check the integrity of the security seal and storage conditions prior to administration.

STORAGE:

• The adequate temperature for the product proper conservation is between 4 and 25º C, away from direct sunlight, in a dry and hygienic place.

• Recyclable container, destroy after use and throw it into waste collectors.

• Protect the environment.

• Do not eat or swallow. Keep out from the reach of children.

Presentation: x 20 ml.
Action
Action: Corticoid anti-inflammatory
  • Quantity: 
Copyright MAXXmarketing Webdesigner GmbH
You are here: Home Anti-Inflammatory Dexa 20